ClinicalTrials.gg
CompletedNCT05012423Updated Sep 25, 2024

FTIH Study of ECC0509 in Healthy Volunteers

A Phase 1 interventional study of Placebo and ECC0509 in Nonalcoholic Steatohepatitis and Osteoarthritis, sponsored by Eccogene. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.

Enrollment
39th of 54
89 · median 264
Started
2021
with 10 others
Phase 1
15 of 54
2 open now
Registered
38th of 54
by date
Lead sponsor
3 of 54
Eccogene

Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 39th largest by enrollment, is one of 11 that started in 2021, is one of 15 in phase 1, and was the 38th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, or all of them as a file.
02

Study summary

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Read the detailed description

This study will be conducted in up to seven cohorts of Single Ascending Dose (SAD) \& 3 cohorts of Multiple Ascending Dose (MAD). SAD will consist of a staggered dosing approach with a dose range from 1mg to 80mg. Staggered dosing approach will not be deployed for MAD cohorts with a dose range of 8mg to 40mg. In the MAD cohort, the effect of food will also be assessed by comparing the PK profile of Day 10 fed conditions against Day 14 fasted conditions.

03

Conditions studied

  • Nonalcoholic Steatohepatitis
  • Osteoarthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy male or non- female
  2. Age ≥18 and ≤65 years old
  3. ≥18.0 and ≤32.0 kg/m2
  4. Male participants agree to use
  5. No abnormal findings in physical examination, 12-lead (ECG), laboratory tests, or medical history
  6. Able to understand and sign

Key Exclusion Criteria:

  1. Significant allergic reactions to any drug.
  2. History of significant drug abuse or alcohol abuse within 1 year prior to screening
  3. Concomitant participation in any study of any nature
  4. Use of any concomitant medication except for the occasional use of acetaminophen (up to 2 g daily)
  5. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
  6. Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol breath test, or medical history which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
89 participants (actual)

Study arms

  • Placebo comparator
    SAD Cohorts 1 to 6: Participants Receiving Placebo

    Participants in each SAD cohort will be randomized to receive placebo.

    Drug: Placebo

  • Experimental
    SAD Cohorts 1 to 6: Participants receiving ECC0509

    Participants in each SAD cohort will be randomized to receive 1 of 6 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, or 60 mg).

    Drug: ECC0509

  • Placebo comparator
    MAD Cohorts 1 to 4: Participants receiving Placebo

    Participants will be randomized to receive a once-daily dose of placebo for 14 days.

    Drug: Placebo

  • Experimental
    MAD Cohorts 1 to 4: Participants receiving ECC0509

    Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses (3 mg, 10 mg, 30 mg, 60 mg) for 14 days.

    Drug: ECC0509

Interventions

  • DrugPlacebo

    Matching Placebo will be administered as oral capsules.

  • ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

  • DrugPlacebo

    Matching Placebo will be given orally during each dosing day.

  • ECC0509 1 mg and 10 mg capsules

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations

    Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21.

Secondary outcomes

  1. ECC0509 PK parameters: Cl/F

    Apparent clearance

    Time frame: SAD: Up to Day 8.

  2. ECC0509 PK parameters: Vz/F

    Apparent volume of distribution

    Time frame: SAD: Up to Day 8.

  3. ECC0509 PK parameter: AUC0-24

    Area under the concentration-time curve from time zero to time 24 hours

    Time frame: MAD: Up to Day 21

  4. ECC0509 PK parameter: Cmax ss

    Maximal observed concentration at steady-state

    Time frame: MAD: Up to Day 21

  5. ECC0509 PK parameter: Tmax ss

    Time when the maximal concentration is observed at steady-state

    Time frame: MAD: Up to Day 21

  6. ECC0509 PK parameter: Tlag ss

    Time prior to the first measurable (non-zero) concentration at steady-state

    Time frame: MAD: Up to Day 21

  7. ECC0509 PK parameters: Cmax

    Maximal observed concentration

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  8. ECC0509 PK parameter: Tmax

    Time when the maximal concentration is observed

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  9. ECC0509 PK parameter: AUC0-t

    Area under the curve up to the last quantifiable time-point

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  10. ECC0509 PK parameter: Cmin ss

    Minimal observed concentration at steady-state

    Time frame: MAD: Up to Day 21

  11. ECC0509 PK parameter: T½ el

    Terminal elimination half-life

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  12. ECC0509 PK parameter: Kel

    Terminal elimination rate constant

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  13. ECC0509 PK parameter: Clss/F

    Apparent body clearance at steady-state

    Time frame: MAD: Up to Day 21

  14. ECC0509 PK parameter: Vz ss/F

    Apparent volume of distribution at steady-state

    Time frame: MAD: Up to Day 21

  15. ECC0509 PK parameter: AUC0-τ

    Area under the concentration-time curve for one dosing interval (τ) at steady state.

    Time frame: MAD: Up to Day 21

  16. ECC0509 PK parameters: AUC0-inf

    Area under the concentration-time curve from time zero to infinity

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  17. ECC0509 PK parameters: Residual area

    Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21

  18. PD Parameter: SSAO

    plasma semicarbazide-sensitive amine oxidase (SSAO) activity.

    Time frame: SAD: Up to Day 8. MAD: Up to Day 21.

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2023, 23 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 23 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Aug 19, 2021
StartActual
Jul 26, 2021
Primary completionActual
Jul 22, 2023
CompletionActual
Jul 22, 2023
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05012423
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Jul 26, 2021
Primary completion
Jul 22, 2023
Completion
Jul 22, 2023
Last update
Sep 25, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ECC0509

Start the discussion